Clinical features and prognosis of drug-induced liver injury in patients with non-alcoholic fatty liver

Table 8 Comparison of autoantibody spectrum in the two groups

Autoantibody	DILI (n = 54)	DILI + NAFL (n = 78)	P value
Antinuclear antibody ANA	33 (61.1)	50 (64.1)	0.727
Anti-mitochondrial Antibodies AMA	2 (3.7)	2 (2.6)	0.707
Anti-smooth muscle antibodies ASMA	1 (1.9)	3 (3.8)	0.888
Anti-dsDNA antibody	0 (0)	1 (1.3)	1
Anti-dsDNA antibody	3 (3.2)	1 (2.3)	0.372
Anti-U1-snRNP antibody	2 (3.7)	0 (0)	0.166
Anti-SSA/Ro60 antibody	5 (9.3)	5 (6.4)	0.543
Anti-SSB/Ro52 antibody	5 (9.3)	3 (3.8)	0.363
Anti-SSB/la antibody	2 (3.7)	2 (2.6)	0.707
Anti-Scl-70 antibody	1 (1.9)	0 (0)	0.409
Anti-matrix antibody	0 (0)	0 (0)
Anti-Jo-1 antibody	0 (0)	0 (0)
Anti-Ribosomal P0 Antibody	0 (0)	0 (0)
P-ANCA	0 (0)	0 (0)
Atypical P-ANCA	0 (0)	0 (0)
Antiproteinase 3, PR3	0 (0)	0 (0)
Antiperoxidase, MPO	0 (0)	0 (0)
Anti-histone antibody	0 (0)	0 (0)
Anti-mitochondrial M2 antibody	0 (0)	2 (2.6)	0.513
Anti-nucleotide protein anti-Sp100	0 (0)	2 (2.6)	0.513
Anti-liver and kidney microparticle antibody LKM1	0 (0)	1 (1.3)	1
Anti-nuclear envelope antibody gp210	1 (1.9)	0 (0)	0.409
Anti-hepatocyte lysate antibody LC1	0 (0)	0 (0)
Anti-soluble liver antigen SLA	0 (0)	0 (0)
Serum perinuclear factor APF	0 (0)	0 (0)
Antikeratin antibody AKA	0 (0)	0 (0)
Anticyclic citrullinated peptide ACCP	1 (1.9)	1 (1.3)	1

DILI: Drug-induced liver injury; NAFL: Nonalcoholic fatty liver.